Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Change in Cash (2018 - 2025)

BioNexus Gene Lab's Change in Cash history spans 8 years, with the latest figure at -$180097.0 for Q3 2025.

  • For Q3 2025, Change in Cash rose 86.11% year-over-year to -$180097.0; the TTM value through Sep 2025 reached -$1.3 million, up 62.42%, while the annual FY2024 figure was -$1.6 million, 167.98% down from the prior year.
  • Change in Cash for Q3 2025 was -$180097.0 at BioNexus Gene Lab, up from -$552249.0 in the prior quarter.
  • Across five years, Change in Cash topped out at $4.4 million in Q3 2023 and bottomed at -$1.6 million in Q4 2023.
  • The 5-year median for Change in Cash is -$279597.0 (2022), against an average of -$75294.7.
  • The largest annual shift saw Change in Cash skyrocketed 563.89% in 2022 before it plummeted 909.32% in 2025.
  • A 5-year view of Change in Cash shows it stood at $423523.0 in 2021, then crashed by 257.42% to -$666705.0 in 2022, then plummeted by 144.36% to -$1.6 million in 2023, then soared by 113.6% to $221617.0 in 2024, then tumbled by 181.26% to -$180097.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Change in Cash are -$180097.0 (Q3 2025), -$552249.0 (Q2 2025), and -$797528.0 (Q1 2025).